

Claims

- 5 1. An oral dosage form comprising an erodable core which comprises 5-[4-
[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a
pharmaceutically acceptable salt or solvate thereof and another
antidiabetic agent, the core having a coating with one or more openings
10 leading to the core, characterised in that the coating is erodable under
predetermined pH conditions.
2. An oral dosage form according to claim 1, comprising,
(i) an erodable core, which core comprises Compound A or a
pharmaceutically acceptable salt or solvate thereof and another
15 antidiabetic agent; and
(ii) an erodable coating around said core, which coating comprises one or
more openings extending substantially completely through said coating
but not substantially penetrating said core and communicating from the
environment of use to said core;
20 wherein release of Compound A or a pharmaceutically acceptable salt or
solvate thereof and the other antidiabetic agent from the erodable core
occurs substantially through the said opening(s) and through erosion of
said erodable coating under pre-determined pH conditions.
- 25 3. An oral dosage form according to claim 1 or claim 2, wherein the erodable
coating an enteric coating.
4. An oral dosage form according to claim 3, wherein the enteric coating is
non-permeable.
30 5. An oral dosage form according to claim 1, wherein the erodable core is
formulated to provide immediate release of both Compound A or a

pharmaceutically acceptable salt or solvate thereof and the other antidiabetic agent.

5 6. An oral dosage form according to claim 1, wherein said other antidiabetic agent is metformin or a pharmaceutically acceptable salt or solvate thereof.

10 7. An oral dosage form according to any preceding claim, wherein said dosage form is a tablet form.

8. According to a further aspect of the present invention, there is provided a process for the preparation of an oral dosage form according to claim 1, which process comprises:

15 (a) preparing an erodable tablet core comprising Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent;

(b) coating the core with a material with pH-dependent erodability; and

(c) creating one or more openings in the coating.

20 9. A method for the treatment and/or prophylaxis of the Disorders of the Invention which method comprises administering an oral dosage form comprising Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, according to claim 1, to a human or non-human mammal in need thereof.

25

30